The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Mon., Feb. 8, 11:31 AM

Slide #5. Jaguar Animal Health, Inc. Secondary Offering

Company: Jaguar Animal Health, Inc. (NASDAQ:JAGX)
Date announced: 2/3/2016
Shares Offered: 2,000,000
Date of Pricing: 2/3/2016
Price Per Share: $2.50
Secondary Offering Details: Jaguar Animal Health, Inc. (Nasdaq: JAGX), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and high-value horses, announced today the pricing of an underwritten public offering of 2,000,000 shares of its common stock at an offering price to the public of $2.50 per share. All of the common stock is being offered by Jaguar Animal Health, Inc. The gross proceeds to Jaguar Animal Health, Inc. from this offering are expected to be approximately $5,000,000 before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Jaguar Animal Health, Inc. has granted the underwriters a 45-day option to purchase up to 300,000 additional shares of common stock to cover over-allotments, if any. The offering is expected to close on February 8, 2016, subject to customary closing conditions.

Jaguar Animal Health is an animal health company focused on developing and commercializing gastrointestinal products for companion and production animals. Canalevia is its prescription drug product candidate for the treatment of various forms of watery diarrhea in dogs. Co. also initiated filing of a rolling new animal drug application, or NADA, with the U.S. Food and Drug Administration, or FDA, for Canalevia for chemotherapy-induced diarrhea, or CID, in dogs. Canalevia is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree.
Open the JAGX Page at The Online Investor »

Company Name:  Jaguar Animal Health Inc
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding JAGX:  1
Total Market Value Held by ETFs:  $771
Total Market Capitalization:  $15.00M
% of Market Cap. Held by ETFs:  0.01%

Open the JAGX Page at The Online Investor (in a new window) »

February 8, 2016    11:31 AM Eastern
Quotes delayed 20 minutes

Strong Buy (4.00 out of 4)
95th percentile
(ranked higher than approx. 95% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.